Molecular Physiology Division, Faculty of Science, Beni-Suef University, Salah Salem St., Beni Suef, 62511, Egypt.
Department of Biochemistry, Faculty of Science, Beni-Suef University, Beni Suef, Egypt.
Clin Exp Med. 2020 May;20(2):231-240. doi: 10.1007/s10238-019-00605-3. Epub 2020 Feb 19.
The achievement of virological response in the treatment of hepatitis C virus (HCV) can improve the extrahepatic manifestations. The present study aimed to investigate the effect of HCV eradication after sofosbuvir/daclatasvir (SOF/DCV) therapy on hematological and inflammatory biomarkers in type 2 diabetic patients infected with HCV genotype 4. Between October 2017 and August 2018, among 145 patients with HCV genotype 4, 30 patients were enrolled in the study based on the fact that they have type 2 diabetes. Enrolled HCV-diabetic patients were treated for 12 weeks with SOF/DCV regimen. Patients were screened by laboratory investigations before treatment (baseline values) and after HCV treatment (post-treatment values). Additionally, 30 healthy individuals were enrolled as a control group. Among the patient's cohort, the sustained virological response was achieved by 100% of the treated patients after 12 weeks of SOF/DCV therapy. Moreover, the levels of insulin resistance (HOMA-IR), nitric oxide, interleukin-1β, red cell distribution width, platelet distribution width, mean platelet volume were improved significantly (P < 0.001) in treated patients after successful viral clearance compared to baseline values. In addition, virological clearance exhibited positive correlations with interleukin-1β, nitric oxide, leukocytes count, red cell distribution width, and mean platelet volume. In conclusion, the data suggest the potential amelioration effect of HCV eradication after treatment with SOF/DCV regimen on the inflammatory status among HCV-diabetic patients which is reflected by the noticeable improvement of altered hematological indices and inflammatory biomarkers.
在丙型肝炎病毒 (HCV) 的治疗中实现病毒学应答可以改善肝外表现。本研究旨在探讨索磷布韦/达拉他韦 (SOF/DCV) 治疗后 HCV 清除对感染 HCV 基因型 4 的 2 型糖尿病患者血液学和炎症生物标志物的影响。2017 年 10 月至 2018 年 8 月，在 145 例 HCV 基因型 4 患者中，根据他们患有 2 型糖尿病这一事实，有 30 例患者被纳入研究。纳入的 HCV 合并糖尿病患者接受 SOF/DCV 方案治疗 12 周。患者在治疗前（基线值）和 HCV 治疗后（治疗后）进行实验室检查筛查。此外，还纳入了 30 名健康个体作为对照组。在患者队列中，100%接受 SOF/DCV 治疗 12 周的患者达到持续病毒学应答。此外，与基线值相比，成功清除病毒后，治疗患者的胰岛素抵抗 (HOMA-IR)、一氧化氮、白细胞介素-1β、红细胞分布宽度、血小板分布宽度和平均血小板体积水平显著改善（P<0.001）。此外，病毒学清除与白细胞介素-1β、一氧化氮、白细胞计数、红细胞分布宽度和平均血小板体积呈正相关。总之，这些数据表明，SOF/DCV 方案治疗后 HCV 清除可能对 HCV 合并糖尿病患者的炎症状态产生潜在的改善作用，这反映在改变的血液学指标和炎症生物标志物的显著改善上。
